Daclatasvir 60 mg Tablets are antiviral medicines used as part of combination treatment for chronic hepatitis C virus (HCV) infection. Daclatasvir is a direct-acting antiviral (DAA) that works by interfering with the hepatitis C virus's ability to multiply. It is commonly used in combination with other antiviral medicines, particularly sofosbuvir, according to the applicable treatment guidelines and product information.
For healthcare providers, pharmaceutical distributors, and medicine buyers looking for information about Daclatasvir 60 mg Tablets, understanding their uses, benefits, dosage considerations, and precautions is important before sourcing or supplying the product.
What Are Daclatasvir 60 mg Tablets?
Daclatasvir 60 mg Tablets contain 60 mg of daclatasvir, generally supplied as daclatasvir dihydrochloride. The medicine belongs to the direct-acting antiviral class and is designed to target hepatitis C virus replication.
WHO has prequalified several 60 mg daclatasvir tablet products, demonstrating that this strength is an established pharmaceutical presentation for hepatitis C treatment.
Daclatasvir 60 mg Tablets Uses
The primary use of Daclatasvir 60 mg Tablets is in the treatment of chronic hepatitis C infection. Daclatasvir is not normally used alone; it is administered as part of a combination antiviral regimen.
WHO product information specifies daclatasvir 60 mg in combination with sofosbuvir for eligible patients. Treatment selection and duration depend on factors such as the patient's clinical condition, treatment history, liver status, and applicable treatment guidelines.
How Does Daclatasvir Work?
Daclatasvir acts directly against the hepatitis C virus by interfering with viral replication. By reducing the virus's ability to multiply, it contributes to lowering HCV levels in the body when used with appropriate companion antiviral therapy.
Modern direct-acting antiviral treatments have significantly improved hepatitis C management. The World Health Organization reports that DAA medicines can cure more than 95% of people with hepatitis C, although the specific regimen and treatment response vary between patients.
Key Benefits of Daclatasvir 60 mg Tablets
Some important characteristics of Daclatasvir 60 mg Tablets include:
- Direct-acting antiviral therapy: Daclatasvir directly targets HCV replication.
- Oral tablet formulation: The medicine is administered orally.
- Combination treatment: It can form part of an effective hepatitis C treatment regimen with other antiviral medicines.
- Established 60 mg strength: WHO has prequalified multiple daclatasvir 60 mg finished pharmaceutical products.
- Global treatment relevance: Daclatasvir-based regimens have been used extensively in hepatitis C treatment, particularly in countries where affordable generic antiviral medicines are available.
The WHO currently identifies sofosbuvir and daclatasvir as one of the widely used and lower-cost DAA treatment combinations in many low- and middle-income countries.
Daclatasvir 60 mg Dosage Information
The appropriate dose and treatment duration should always be determined by a qualified healthcare professional. Daclatasvir should be used with the companion antiviral medicine specified by the treatment regimen.
For one WHO-prequalified 60 mg product, patients weighing 26 kg or more may receive 60 mg once daily when used with sofosbuvir, while treatment duration can vary according to treatment history, cirrhosis status, and other clinical factors.
Patients should not change the dose, discontinue treatment, or combine Daclatasvir with other medicines without medical advice.
Side Effects and Precautions
As with other prescription medicines, Daclatasvir may cause unwanted effects in some patients. Patients should discuss any unusual or persistent symptoms with their healthcare provider.
Drug interactions are particularly important. Certain medicines can reduce daclatasvir exposure and potentially decrease treatment effectiveness. WHO patient information specifically identifies medicines such as phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, dexamethasone, and St. John's wort as medicines that may interact with daclatasvir.
A complete medication history should therefore be reviewed before treatment begins.
Storage of Daclatasvir 60 mg Tablets
Storage requirements depend on the specific manufacturer's product. For example, WHO-prequalified daclatasvir 60 mg products include storage instructions of not above 30°C, with some products requiring storage in the original container. Buyers and distributors should always follow the storage conditions printed on the specific product packaging and approved product information.
Buying or Sourcing Daclatasvir 60 mg Tablets
Pharmaceutical distributors, hospitals, healthcare organizations, and authorized medicine buyers looking to source Daclatasvir 60 mg Tablets should verify the manufacturer, formulation, strength, packaging, regulatory status, batch details, expiry date, and applicable import requirements before placing an order.
For international pharmaceutical sourcing, documentation and destination-country regulations should also be checked before shipment.
Frequently Asked Questions
What are Daclatasvir 60 mg Tablets used for?
Daclatasvir 60 mg Tablets are used as part of combination antiviral treatment for chronic hepatitis C virus infection. They are generally used with another antiviral medicine rather than as monotherapy.
Can Daclatasvir 60 mg be taken alone?
Daclatasvir is generally used as part of a combination treatment regimen. Patients should follow the regimen prescribed by their healthcare provider.
What is Daclatasvir 60 mg used with?
A commonly documented regimen is daclatasvir with sofosbuvir. The appropriate combination depends on current clinical guidelines and the patient's circumstances.
Is Daclatasvir a prescription medicine?
Daclatasvir is a prescription antiviral medicine and should be used under appropriate medical supervision.
Who should determine the dosage?
A qualified healthcare professional should determine the dose and treatment duration based on the patient's clinical condition, treatment history, liver status, other medicines, and applicable treatment guidelines.
Conclusion
Daclatasvir 60 mg Tablets are an established direct-acting antiviral medicine used in combination treatment for chronic hepatitis C. Their oral formulation, established 60 mg strength, and inclusion in WHO-prequalified pharmaceutical products make daclatasvir an important medicine in hepatitis C treatment programs.
For pharmaceutical buyers and distributors, sourcing should focus on verified product quality, appropriate documentation, packaging, storage requirements, regulatory compliance, and the import requirements of the destination market.